Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
$14.46
-$0.18(-1.98%)
At close: 4:00 PM EST
$14.46
-$0.18(-1.98%)
Day’s Range― - ―
52-Week Range$5.51 - $14.48
Previous CloseN/A
Volume320.41K
Average Volume (3M)3.40M
Market Cap
$4.54B
Enterprise Value$4.81B
Total Cash (Recent Filing)$293.54M
Total Debt (Recent Filing)$483.32M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
May 13, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding314,000,700
10 Day Avg. Volume2,310,853
30 Day Avg. Volume3,403,546
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)16.01
Price to Sales (P/S)6.92
P/FCF Ratio147.11
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.58
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda89.38
Forecast
1Y Price Target
$14.50Price Target Upside0.28% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.33
Revenue Forecast (FY)$751.14M
Bulls Say, Bears Say
Bulls Say
Acquisition Cash ConsiderationShareholders are set to receive a cash payment per share upon completion of the announced acquisition by BioMarin, providing a clear cash outcome contingent on approvals.
Geographic ExpansionGrowth of the pom/opf product line and expansion into European markets supports commercial diversification and new revenue opportunities.
Product DemandStronger-than-expected Galafold sales indicate rising demand for the lead therapy, supporting revenue momentum and commercial durability.
Bears Say
Analyst Sentiment And Upside LimitationAnalyst downgrades to Hold and views that acquisition-driven upside has been realized suggest limited prospects for further stock appreciation.
Guidance UncertaintyWithholding of financial guidance because of the expected acquisition increases investor uncertainty about near-term performance and valuation.
Limited Takeover CompetitionLimited interest from other pharmaceutical bidders reduces the likelihood of competing offers, constraining potential upside from a bidding process.
Amicus News
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $5.51 and its highest was $14.48 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $4.54B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 30 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Feb 20, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.071 by -$0.061.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is 0.04.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 314,000,700 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of $0.01 in its last earnings report, missing expectations of $0.071. Following the earnings report the stock price went up 0.139%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amicus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.50 (0.28% Upside)
$14.50 (0.28% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 18.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.11%
12-Months-Change
Fundamentals
Return on Equity
-12.02%
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
FOLD Stock 12 Month Forecast
Average Price Target
$14.50
▲(0.28% Upside)
Technical Analysis
Catalyst Pharma
―
Travere Therapeutics
―
Ocular Therapeutix
―
Immunovant
―
Disc Medicine
―
Ownership Overview
1.01% Insiders
27.63% Mutual Funds
41.85% Other Institutional Investors
9.27% Public Companies and
Individual Investors